Thanks at @davo47 for locking in option 4 seemed to do the trick.
The SPP was a huge success and happy with the scale back even though mine was at 50% and held since IPO. Alternative would have been full allocation and undersubscribed - lag in PoC.
Management put it all out there and this shows from the numbers. Firstly we went for x3 times an average retail raise and $11m+ more than the next highest retail biotech raise that I found in some sample data.
Looking forward to 2022, happy to buy on market with scale-back refund and move on!
Ann: SPP Closing Deadline Reminder & Investor Briefing Recording, page-80
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |